vs
BYLINE BANCORP, INC.（BY）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是BYLINE BANCORP, INC.的1.5倍（$168.4M vs $112.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 9.0%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 6.4%）
Byline Bank是总部位于美国伊利诺伊州芝加哥的银行，为银行控股公司Byline Bancorp, Inc.的核心子公司，同时是全美SBA 7(a)贷款项目的第四大放贷机构，为客户提供专业的银行及融资相关服务。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
BY vs ESPR — 直观对比
营收规模更大
ESPR
是对方的1.5倍
$112.4M
营收增速更快
ESPR
高出134.7%
9.0%
两年增速更快
ESPR
近两年复合增速
6.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.4M | $168.4M |
| 净利润 | $37.6M | — |
| 毛利率 | — | — |
| 营业利润率 | — | 50.6% |
| 净利率 | 33.4% | — |
| 营收同比 | 9.0% | 143.7% |
| 净利润同比 | 33.0% | — |
| 每股收益（稀释后） | $0.83 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BYESPR
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $168.4M | ||
| Q3 25 | $115.7M | $87.3M | ||
| Q2 25 | $110.5M | $82.4M | ||
| Q1 25 | $103.1M | $65.0M | ||
| Q4 24 | $104.7M | $69.1M | ||
| Q3 24 | $101.8M | $51.6M | ||
| Q2 24 | $99.4M | $73.8M |
净利润BYESPR
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | — | ||
| Q3 25 | $37.2M | $-31.3M | ||
| Q2 25 | $30.1M | $-12.7M | ||
| Q1 25 | $28.2M | $-40.5M | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $30.3M | $-29.5M | ||
| Q2 24 | $29.7M | $-61.9M |
营业利润率BYESPR
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 50.6% | ||
| Q3 25 | 43.1% | -11.4% | ||
| Q2 25 | 35.2% | 8.6% | ||
| Q1 25 | 36.4% | -34.0% | ||
| Q4 24 | 38.6% | -6.4% | ||
| Q3 24 | 39.3% | -31.0% | ||
| Q2 24 | 40.4% | 3.5% |
净利率BYESPR
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | — | ||
| Q3 25 | 32.1% | -35.9% | ||
| Q2 25 | 27.2% | -15.4% | ||
| Q1 25 | 27.4% | -62.2% | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.8% | -57.2% | ||
| Q2 24 | 29.9% | -83.9% |
每股收益（稀释后）BYESPR
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.32 | ||
| Q3 25 | $0.82 | $-0.16 | ||
| Q2 25 | $0.66 | $-0.06 | ||
| Q1 25 | $0.64 | $-0.21 | ||
| Q4 24 | $0.68 | $-0.14 | ||
| Q3 24 | $0.69 | $-0.15 | ||
| Q2 24 | $0.68 | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.4M | $167.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $-302.0M |
| 总资产 | $9.9B | $465.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BYESPR
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $167.9M | ||
| Q3 25 | $259.0M | $92.4M | ||
| Q2 25 | $218.3M | $86.1M | ||
| Q1 25 | $421.3M | $114.6M | ||
| Q4 24 | $563.1M | $144.8M | ||
| Q3 24 | $452.6M | $144.7M | ||
| Q2 24 | $730.5M | $189.3M |
股东权益BYESPR
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $-302.0M | ||
| Q3 25 | $1.2B | $-451.4M | ||
| Q2 25 | $1.2B | $-433.5M | ||
| Q1 25 | $1.1B | $-426.2M | ||
| Q4 24 | $1.1B | $-388.7M | ||
| Q3 24 | $1.1B | $-370.2M | ||
| Q2 24 | $1.0B | $-344.2M |
总资产BYESPR
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $465.9M | ||
| Q3 25 | $9.8B | $364.0M | ||
| Q2 25 | $9.7B | $347.1M | ||
| Q1 25 | $9.6B | $324.0M | ||
| Q4 24 | $9.5B | $343.8M | ||
| Q3 24 | $9.4B | $314.1M | ||
| Q2 24 | $9.6B | $352.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $45.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BYESPR
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $45.2M | ||
| Q3 25 | $38.3M | $-4.3M | ||
| Q2 25 | $16.3M | $-31.4M | ||
| Q1 25 | $27.1M | $-22.6M | ||
| Q4 24 | $175.2M | $-35.0M | ||
| Q3 24 | $19.8M | $-35.3M | ||
| Q2 24 | $40.1M | $-7.2M |
自由现金流BYESPR
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $15.2M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $171.2M | — | ||
| Q3 24 | $19.1M | $-35.5M | ||
| Q2 24 | $39.4M | $-7.3M |
自由现金流率BYESPR
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | — | ||
| Q3 25 | 32.8% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 24.3% | — | ||
| Q4 24 | 163.5% | — | ||
| Q3 24 | 18.8% | -68.7% | ||
| Q2 24 | 39.7% | -9.9% |
资本支出强度BYESPR
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.0% | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 1.0% | 0.0% | ||
| Q1 25 | 2.0% | 0.0% | ||
| Q4 24 | 3.8% | 0.0% | ||
| Q3 24 | 0.6% | 0.3% | ||
| Q2 24 | 0.7% | 0.1% |
现金转化率BYESPR
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BY
暂无分部数据
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
